植物源四价病毒样颗粒流感疫苗批次间一致性III期随机观察者盲法试验
该III期随机观察者盲法试验将1200名18-49岁健康成人按1:1:1分配接种三批次植物源四价病毒样颗粒流感疫苗(每株30 μg HA),评估批次间免疫原性一致性。结果显示所有四株疫苗血凝抑制抗体应答均达到CBER设定的血清转化率和血清保护率标准,批次间几何平均滴度比值的95%CI均落在0.67-1.5内,安全性良好。
要点
- 植物源QVLP疫苗三批次间血凝抑制抗体几何平均滴度比值95%CI均落在0.67-1.5内,批次一致性达标。
- 所有四株疫苗血清转化率≥40%、血清保护率≥70%,符合CBER标准。
- 安全性良好,征集性不良事件多为轻度和一过性,与灭活流感疫苗类似。
核心结论
- 植物源四价病毒样颗粒流感疫苗三批次间免疫原性一致,安全性良好,支持其生产可重复性。
研究设计与样本
- III期随机观察者盲法批次间一致性试验(NCT03321968),1200名18-49岁健康成人按1:1:1接种三批次QVLP(每株30 μg HA,0.5 mL肌注)。
主要发现
- 受试者 demographics 组间相似,研究程序依从性96.3%;女性占54.8%,平均年龄29.9±9.01岁,种族分布为白人77.8%、亚裔15.6%、黑种人5.8%、其他0.8%。
- 所有四株疫苗的HI应答均达到CBER血清转化标准(SCR≥40%)和血清保护标准(SPR≥70%)。
- 每批次所有四株疫苗的HI滴度几何平均倍数上升均≥2.5。
- 批次间一致性达标:所有四株疫苗接种后第21天几何平均滴度比值的95%CI均落在0.67-1.5内。
- 未发现安全性问题;征集性不良事件多为轻度和一过性,与灭活流感疫苗接种后报告的情况类似。
关键数值与推荐
- 血清转化率(SCR)标准:≥40%;血清保护率(SPR)标准:≥70%。
- 批次间一致性标准:接种后第21天几何平均滴度比值的95%CI落在0.67-1.5内。
- HI滴度几何平均倍数上升标准:≥2.5。
- 疫苗剂量:每株30 μg HA,0.5 mL肌注。
临床怎么用
- 该植物源QVLP疫苗在18-49岁成人中免疫原性达标且批次间一致,可作为鸡蛋依赖型流感疫苗生产的替代平台。
- 接种后第21天HI抗体应答达到CBER标准,支持进一步开展效力研究和人群应用评估。
局限性
- 试验仅纳入18-49岁健康成人,未覆盖儿童、老年人及基础疾病人群。
- 仅评估至接种后第21天的HI抗体,未报告长期免疫持久性数据。
- 未报告临床效力终点,仅基于免疫原性替代指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The global reliance on eggs to produce most influenza vaccines has several limitations and new approaches to influenza vaccine production are needed. Herein we describe a phase 3, lot-to-lot consistency trial (NCT03321968) of a quadrivalent, recombinant, virus-like particle (VLP) influenza vaccine produced in plants. This platform is based on transient expression of proteins in Nicotiana benthamiana and yields VLPs bearing hemagglutinin (HA) protein trimers that are combined in a quadrivalent vaccine (QVLP). METHODS: The HAs targeted in this study were A/California/07/2009 H1N1, A/Hong Kong/4801/2014 H3N2, B/Brisbane/60/08 and B/Phuket/3073/2013: recommended for the 2016-2017 Northern Hemisphere season. Healthy adults 18-49 years of age (n = 1200) were randomized 1:1:1 to receive a 0.5 mL intramuscular injection of QVLP (30 μg HA/strain) from three sequential lots. Local and systemic reactions were monitored for 21 days post-vaccination and blood was collected pre-vaccination and at day 21 (D21) after vaccination to measure hemagglutination inhibition (HI) antibodies. RESULTS: Subject demographics were similar between groups and compliance with study procedures was 96.3%. The study population was 54.8% female, the mean age (±SD) was 29.9 ± 9.01 and the racial distribution was 77.8% Caucasian, 15.6% Asian, 5.8% Black/African American and 0.8% other. The HI responses met the Center for Biologics Evaluation and Research criteria for seroconversion (SCR ≥ 40%) and seroprotection rates (SPR ≥ 70%). The geometric mean fold rise in HI titers was ≥ 2.5 for all 4 strains for each lot. Lot-to-lot consistency was met with the 95% confidence intervals of the D21 mean geometric titre ratios falling between 0.67 and 1.5 for all four strains. No safety concerns were identified. Solicited adverse events were generally mild and transient: typical for what is reported after inactivated influenza vaccines. CONCLUSIONS: This study supported earlier findings of the safety profile and immunogenicity of the plant-derived QVLP and demonstrated the consistency with which it can be produced.
引用
- Ward BJ, Séguin A, Couillard J, et al. Phase III: Randomized observer-blind trial to evaluate lot-to-lot consistency of a new plant-derived quadrivalent virus like particle influenza vaccine in adults 18-49 years of age. Vaccine. 2021. PMID: 33581920. doi:10.1016/j.vaccine.2021.01.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。